Read about NIAID’s study suggesting that VSV is a viable delivery system, or vector, for sequential vaccines against Lassa and Ebola viruses.
Ebola and Marburg hemorrhagic fevers are acute viral diseases that often lead to severe illness and death in humans and other primates. The infections typically affect multiple organs in the body and are often accompanied by hemorrhage (bleeding). Once the virus has been transmitted from an animal host to a human, it can then spread through person-to-person contact.Researchers in the NIAID Division of Intramural Research and at the Institute’s Vaccine Research Center as well as NIAID-supported scientists in external facilities are studying all aspects of Ebola and Marburg viruses, how they spread, and how they cause disease. Investigators seek better ways to diagnose and treat Ebola and Marburg fevers, including promising work on vaccines.
NIH Begins Early Human Clinical Trial of VSV Ebola Vaccine—Oct. 22, 2014
Media Availability: NIH Grants License Agreement for Candidate Ebola Vaccines—Oct. 15, 2014
Media Availability: Rapid and Durable Protection Against Ebola Virus With New Vaccine Regimens—Sept. 7, 2014
NIH to Launch Human Safety Study of Ebola Vaccine Candidate—Aug. 28, 2014
All Ebola/Marburg News Releases
News From NIAID-Supported Institutions
Last Updated October 22, 2014